Venus Remedies secures GMP certification for antibiotic carbapenem facility in Moldova
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Zydus Lifesciences and SBL have mutually decided to extend the date of closing upto March 31, 2025
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
This facility marks a significant milestone in transforming the global food industr
New research labs and process development services to enable next generation therapeutics
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
This approval reflects company’s unwavering commitment that the quality assurance
Subscribe To Our Newsletter & Stay Updated